$DTIL
PRECISION BIOSCIENCES INC

2022 Q4 Form 10-Q Financial Statement

#000095017022022893 Filed on November 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $10.60M $7.363M $24.04M
YoY Change 67.19% -69.37% 226.44%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.02M $10.33M $9.638M
YoY Change -5.69% 7.22% 12.99%
% of Gross Profit
Research & Development $19.42M $19.96M $24.04M
YoY Change -21.21% -16.96% -3.37%
% of Gross Profit
Depreciation & Amortization $1.960M $1.941M $2.264M
YoY Change -9.89% -14.27% 1.52%
% of Gross Profit
Operating Expenses $31.09M $30.29M $35.58M
YoY Change -16.18% -14.85% 6.5%
Operating Profit -$22.93M -$11.54M
YoY Change 98.67% -55.68%
Interest Expense $3.545M $405.0K $55.00K
YoY Change 43.23% 636.36% 83.33%
% of Operating Profit
Other Income/Expense, Net -$1.016M $263.0K
YoY Change -486.31% 839.29%
Pretax Income -$28.49M -$23.95M -$11.28M
YoY Change 27.81% 112.31% -56.65%
Income Tax
% Of Pretax Income
Net Earnings -$28.49M -$23.95M -$11.28M
YoY Change 27.81% 112.31% -56.65%
Net Earnings / Revenue -268.81% -325.22% -46.93%
Basic Earnings Per Share -$0.22 -$0.19
Diluted Earnings Per Share -$0.26 -$0.22 -$189.1K
COMMON SHARES
Basic Shares Outstanding 111.0M 110.8M 59.66M
Diluted Shares Outstanding 110.8M 59.66M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $189.6M $212.1M $160.5M
YoY Change 31.96% 32.14% 54.15%
Cash & Equivalents $189.6M $212.1M $160.5M
Short-Term Investments
Other Short-Term Assets $1.257M $307.0K $22.09M
YoY Change 643.79% -98.61% 166.13%
Inventory
Prepaid Expenses $7.552M $12.29M
Receivables $720.0K $715.0K $488.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $199.1M $225.4M $183.0M
YoY Change 23.09% 23.12% 49.31%
LONG-TERM ASSETS
Property, Plant & Equipment $20.19M $21.79M $37.05M
YoY Change -19.73% -41.18% -14.24%
Goodwill
YoY Change
Intangibles $1.348M $1.969M
YoY Change -34.18%
Long-Term Investments $2.172M $3.091M $812.0K
YoY Change -42.1% 280.67%
Other Assets $2.570M $9.517M $4.216M
YoY Change -44.62% 125.74% 163.5%
Total Long-Term Assets $39.06M $46.37M $44.15M
YoY Change -21.47% 5.02% -4.23%
TOTAL ASSETS
Total Short-Term Assets $199.1M $225.4M $183.0M
Total Long-Term Assets $39.06M $46.37M $44.15M
Total Assets $238.2M $271.7M $227.2M
YoY Change 12.61% 19.6% 34.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.225M $1.061M $486.0K
YoY Change 7.08% 118.31% -51.4%
Accrued Expenses $11.50M $10.45M $9.679M
YoY Change -8.82% 8.01% -17.97%
Deferred Revenue $46.19M $48.41M
YoY Change 117.44%
Short-Term Debt $0.00 $0.00 $2.454M
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $59.66M $61.15M $36.48M
YoY Change 65.83% 67.64% -13.12%
LONG-TERM LIABILITIES
Long-Term Debt $22.22M $22.17M $0.00
YoY Change 796.81%
Other Long-Term Liabilities $201.0K $217.0K $89.28M
YoY Change 356.82% -99.76% 41.94%
Total Long-Term Liabilities $201.0K $217.0K $89.28M
YoY Change 356.82% -99.76% 41.94%
TOTAL LIABILITIES
Total Short-Term Liabilities $59.66M $61.15M $36.48M
Total Long-Term Liabilities $201.0K $217.0K $89.28M
Total Liabilities $177.7M $187.4M $125.8M
YoY Change 47.71% 48.98% 19.92%
SHAREHOLDERS EQUITY
Retained Earnings -$428.3M -$399.8M
YoY Change 35.25%
Common Stock $489.7M $485.2M
YoY Change 19.79%
Preferred Stock
YoY Change
Treasury Stock (at cost) $952.0K $952.0K
YoY Change 0.0%
Treasury Stock Shares
Shareholders Equity $60.43M $84.38M $101.4M
YoY Change
Total Liabilities & Shareholders Equity $238.2M $271.7M $227.2M
YoY Change 12.61% 19.6% 34.69%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$28.49M -$23.95M -$11.28M
YoY Change 27.81% 112.31% -56.65%
Depreciation, Depletion And Amortization $1.960M $1.941M $2.264M
YoY Change -9.89% -14.27% 1.52%
Cash From Operating Activities -$21.84M $29.19M -$23.90M
YoY Change -7.76% -222.09% 7.58%
INVESTING ACTIVITIES
Capital Expenditures $632.0K -$1.090M -$1.483M
YoY Change -141.99% -26.5% 41.24%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$632.0K -$1.090M -$1.483M
YoY Change -58.01% -26.5% 41.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -180.0K 11.92M
YoY Change -100.0% -101.51% 2148.3%
NET CHANGE
Cash From Operating Activities -21.84M 29.19M -23.90M
Cash From Investing Activities -632.0K -1.090M -1.483M
Cash From Financing Activities 0.000 -180.0K 11.92M
Net Change In Cash -22.48M 27.92M -13.47M
YoY Change 33.72% -307.21% -40.76%
FREE CASH FLOW
Cash From Operating Activities -$21.84M $29.19M -$23.90M
Capital Expenditures $632.0K -$1.090M -$1.483M
Free Cash Flow -$22.48M $30.28M -$22.42M
YoY Change 1.35% -235.03% 5.91%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
2391000
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001357874
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Registrant Name
EntityRegistrantName
PRECISION BIOSCIENCES INC
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38841
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-4206017
dei Entity Address Address Line1
EntityAddressAddressLine1
302 East Pettigrew St.
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite A-100
dei Entity Address City Or Town
EntityAddressCityOrTown
Durham
dei Entity Address State Or Province
EntityAddressStateOrProvince
NC
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
27701
dei City Area Code
CityAreaCode
919
dei Local Phone Number
LocalPhoneNumber
314-5512
dei Security12b Title
Security12bTitle
Common Stock, par value $0.000005 per share
dei Trading Symbol
TradingSymbol
DTIL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
110958955
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
212051000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
143663000
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
715000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
488000
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
12292000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
17434000
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
307000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
169000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
225365000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
161754000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21791000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25154000
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1969000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2048000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3289000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4180000
CY2022Q3 us-gaap Equity Securities Fvni Noncurrent
EquitySecuritiesFVNINoncurrent
3091000
CY2021Q4 us-gaap Equity Securities Fvni Noncurrent
EquitySecuritiesFVNINoncurrent
3091000
CY2021Q4 us-gaap Equity Method Investments
EquityMethodInvestments
3751000
CY2022Q3 us-gaap Notes Receivable Net
NotesReceivableNet
6711000
CY2021Q4 us-gaap Notes Receivable Net
NotesReceivableNet
6879000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
9517000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4641000
CY2022Q3 us-gaap Assets
Assets
271733000
CY2021Q4 us-gaap Assets
Assets
211498000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1061000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1144000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5188000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6765000
CY2022Q3 dtil Accrued Clinical And Research And Development Expenses
AccruedClinicalAndResearchAndDevelopmentExpenses
3285000
CY2021Q4 dtil Accrued Clinical And Research And Development Expenses
AccruedClinicalAndResearchAndDevelopmentExpenses
4028000
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
48405000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
21244000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1981000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1822000
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1228000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
977000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
61148000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
35980000
CY2022Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
90510000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
67015000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3305000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4813000
CY2022Q3 us-gaap Long Term Debt
LongTermDebt
22173000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
2478000
CY2022Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
10000000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
10000000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
217000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
44000
CY2022Q3 us-gaap Liabilities
Liabilities
187353000
CY2021Q4 us-gaap Liabilities
Liabilities
120330000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000005
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000005
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
111745219
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
110934747
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61712577
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
60902105
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
485155000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
408795000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-399824000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-316675000
CY2022Q3 us-gaap Treasury Stock Value
TreasuryStockValue
952000
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
952000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
84380000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
91168000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
271733000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
211498000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7363000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24036000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14500000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
109190000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19959000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25940000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
62867000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
88768000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10334000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9638000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
31510000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29074000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
30293000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
35578000
us-gaap Operating Expenses
OperatingExpenses
94377000
us-gaap Operating Expenses
OperatingExpenses
117842000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-22930000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11542000
us-gaap Operating Income Loss
OperatingIncomeLoss
-79877000
us-gaap Operating Income Loss
OperatingIncomeLoss
-8652000
CY2021Q3 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
274000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
274000
CY2022Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1783000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-4183000
CY2022Q3 us-gaap Interest Expense
InterestExpense
405000
CY2021Q3 us-gaap Interest Expense
InterestExpense
55000
us-gaap Interest Expense
InterestExpense
625000
us-gaap Interest Expense
InterestExpense
79000
CY2022Q3 us-gaap Interest Income Other
InterestIncomeOther
1172000
CY2021Q3 us-gaap Interest Income Other
InterestIncomeOther
44000
us-gaap Interest Income Other
InterestIncomeOther
1536000
us-gaap Interest Income Other
InterestIncomeOther
145000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1016000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
263000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3272000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
340000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-23946000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-11279000
us-gaap Net Income Loss
NetIncomeLoss
-83149000
us-gaap Net Income Loss
NetIncomeLoss
-8312000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
110849196
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
110849196
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59657677
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59657677
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
80127701
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
80127701
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58018550
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58018550
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
44425000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1297000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
418000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3632000
CY2021Q1 dtil Stock Issued During Period Value Collaboration Partners
StockIssuedDuringPeriodValueCollaborationPartners
27739000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-18689000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
58822000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1353000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3896000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
14826000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
21656000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
100553000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3393000
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
386000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4551000
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3839000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-11279000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
101443000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
91168000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
340000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
282000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4390000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1647000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-28168000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
69659000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
38000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5138000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
47670000
CY2022Q2 dtil Stock Issued During Period Value Collaboration Partners
StockIssuedDuringPeriodValueCollaborationPartners
11553000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-31035000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
103023000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9000
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
161000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5133000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-23946000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
84380000
us-gaap Profit Loss
ProfitLoss
-83149000
us-gaap Profit Loss
ProfitLoss
-8312000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
5838000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
6806000
us-gaap Share Based Compensation
ShareBasedCompensation
14661000
us-gaap Share Based Compensation
ShareBasedCompensation
12079000
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
-58000
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
-23000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
210000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
42000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
891000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
897000
us-gaap Other Noncash Income
OtherNoncashIncome
17894000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
274000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-4183000
dtil Amortization Of Discount On Note Receivable
AmortizationOfDiscountOnNoteReceivable
264000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-5142000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
323000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
227000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-9512000
dtil Increase Decrease In Other Assets And Other Current Assets
IncreaseDecreaseInOtherAssetsAndOtherCurrentAssets
4689000
dtil Increase Decrease In Other Assets And Other Current Assets
IncreaseDecreaseInOtherAssetsAndOtherCurrentAssets
-47000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-187000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
240000
dtil Increase Decrease In Accrued Other Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedOtherExpensesAndOtherCurrentLiabilities
-2237000
dtil Increase Decrease In Accrued Other Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedOtherExpensesAndOtherCurrentLiabilities
-976000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
37209000
dtil Increase Decrease In Lease Liability And Right To Use Asset Other Than Amortization Net
IncreaseDecreaseInLeaseLiabilityAndRightToUseAssetOtherThanAmortizationNet
1349000
dtil Increase Decrease In Lease Liability And Right To Use Asset Other Than Amortization Net
IncreaseDecreaseInLeaseLiabilityAndRightToUseAssetOtherThanAmortizationNet
1430000
dtil Increase Decrease In Contract Liability
IncreaseDecreaseInContractLiability
-10000000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23910000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
12828000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
2687000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
3548000
dtil Payments To Purchase Intangible Assets
PaymentsToPurchaseIntangibleAssets
750000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2687000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4298000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
387000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5757000
dtil Proceeds From Employee Stock Purchase Plan
ProceedsFromEmployeeStockPurchasePlan
443000
dtil Proceeds From Employee Stock Purchase Plan
ProceedsFromEmployeeStockPurchasePlan
804000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
49345000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
18130000
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
25000000
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
35000000
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
19810000
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
2465000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
13000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
94985000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
62143000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
68388000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
70673000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
143663000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
89798000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
212051000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
160471000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
232000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
695000
us-gaap Interest Paid Net
InterestPaidNet
422000
us-gaap Interest Paid Net
InterestPaidNet
36000
dtil Unsettled At The Market Issuances Of Common Stock Included In Other Current Assets
UnsettledAtTheMarketIssuancesOfCommonStockIncludedInOtherCurrentAssets
549000
dtil Contract Liability Accrual Related To Servier Program Purchase Agreement Milestones
ContractLiabilityAccrualRelatedToServierProgramPurchaseAgreementMilestones
10000000
us-gaap Other Significant Noncash Transaction Value Of Consideration Received1
OtherSignificantNoncashTransactionValueOfConsiderationReceived1
17894000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2006-01-26
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
10800000
CY2019Q2 dtil Common And Preferred Stocks Shares Authorized
CommonAndPreferredStocksSharesAuthorized
210000000
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000005
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5133000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4551000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14661000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12079000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8034
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7925
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0311
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0242
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y21D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
CY2022Q3 dtil Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Fair Value Per Option
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValuePerOption
1.09
dtil Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Fair Value Per Option
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValuePerOption
1.94
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9920314
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.28
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
6191412
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.80
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
330359
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.17
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
1971964
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
9.65
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13809403
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.52
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
700000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
14900000
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
34700000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M
CY2022Q3 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2021Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
569000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2323000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1594000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
529000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
545000
CY2022Q3 dtil Lessee Operating Lease Liability Payments Due In Five Years And Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueInFiveYearsAndThereafter
372000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5932000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
646000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
5286000
CY2022Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.0700
CY2022Q3 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.0800
CY2022Q3 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-23946000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-11279000
us-gaap Net Income Loss
NetIncomeLoss
-83149000
us-gaap Net Income Loss
NetIncomeLoss
-8312000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
110849196
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
110849196
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59657677
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59657677
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
80127701
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
80127701
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58018550
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58018550
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3613170
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7259599
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3928739
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6102881
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1

Files In Submission

Name View Source Status
0000950170-22-022893-index-headers.html Edgar Link pending
0000950170-22-022893-index.html Edgar Link pending
0000950170-22-022893.txt Edgar Link pending
0000950170-22-022893-xbrl.zip Edgar Link pending
dtil-20220930.htm Edgar Link pending
dtil-20220930.xsd Edgar Link pending
dtil-ex10_2.htm Edgar Link pending
dtil-ex10_3.htm Edgar Link pending
dtil-ex10_4.htm Edgar Link pending
dtil-ex10_5.htm Edgar Link pending
dtil-ex10_6.htm Edgar Link pending
dtil-ex31_1.htm Edgar Link pending
dtil-ex31_2.htm Edgar Link pending
dtil-ex32_1.htm Edgar Link pending
dtil-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
dtil-20220930_def.xml Edgar Link unprocessable
dtil-20220930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
dtil-20220930_pre.xml Edgar Link unprocessable
dtil-20220930_htm.xml Edgar Link completed
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
dtil-20220930_cal.xml Edgar Link unprocessable